Pharma BD Deal Intelligence
A $1.4B acquisition that gave AbbVie a neuroscience pipeline addition through Aliada Therapeutics. No deal terms beyond the headline price or asset-level detail were disclosed, leaving the strategic rationale largely unproven at announcement.
AbbVie acquired Aliada Therapeutics for $1.4B for neuroscience pipeline.
AbbVie adds another Alzheimer's prospect with $1.4B Aliada Therapeutics acquisition leveraging blood-brain barrier crossing technology.
AbbVie signs agreement to acquire Aliada for $1.4 billion for Alzheimer and neuroscience pipeline.
Source summaries from our enrichment pipeline; follow links for originals.
All 8 sources with sentiment breakdown →
AbbVie acquired Aliada Therapeutics for $1.4B for neuroscience pipeline.
500K US cases/yr · $15.0B Global Alzheimer's Market (2025E)
ALIA-1758 (now ABBV-1758) is an anti-pyroglutamate amyloid beta (3pE-Abeta) antibody delivered across the blood-brain barrier by Aliada's MODEL (Modular Delivery) platform, which exploits the transferrin receptor (TfR) and CD98; ALIA-1758 specifically uses TfR to carry the 3pE-Abeta antibody into the brain for amyloid-plaque clearance in Alzheimer's disease. Its first-in-human Phase 1 single-ascending-dose safety/tolerability/PK trial (NCT06406348, 53 healthy adults) completed in April 2025. The asset appears in AbbVie's April 2026 pipeline update as ABBV-1758 for Alzheimer's disease.
Anti-amyloid: Leqembi (Eisai/Biogen), Kisunla (Lilly). BBB-crossing technology could enable more efficient delivery, lower doses, reduced ARIA.
AbbVie completed $1.4B acquisition of Aliada Therapeutics, gaining ALIA-1758, brain-penetrant anti-amyloid antibody using novel BBB-crossing technology.
First-in-human single-ascending-dose Phase 1 trial (NCT06406348, 53 healthy adults) of ALIA-1758/ABBV-1758 reached actual completion on 2025-04-22.
BBB-crossing technology could be transformative for CNS delivery. ALIA-1758 in early Alzheimer's development. High-risk, high-reward $1.4B platform bet.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| AbbVie Inc. / Aliada Therapeutics (this deal) | 2024 | $1.4B | 52 |
| AbbVie Inc. / Boehringer Ingelheim GmbH | 2016 | $2.2B | 95 |
| AbbVie Inc. / Genmab A/S | 2020 | $3.9B | 81 |
| AbbVie Inc. / Pharmacyclics Inc. | 2015 | $21.0B | 79 |
| AbbVie Inc. / Apogee Therapeutics, Inc. | 2026 | $10.9B | 72 |
| AbbVie Inc. / ImmunoGen Inc. | 2023 | $10.1B | 69 |
| AbbVie Inc. / Gilgamesh Pharmaceuticals Inc. | 2024 | $2.0B | 64 |
← Browse all deals · How we score deals
More: 2024 deals · AbbVie Inc. deals · Neurology deals